Leonard Zehr, Author at BioTuesdays

Developments

Titan’s Probuphine highlighted as a potential game changer

Britain’s Computer Business Review has selected Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant as one of 10 future technologies that will change the world, along with autonomous vehicles, bionic exoskeletons...

November 18, 2016

Markets

Ladenburg upgrades Repros Therapeutics to buy

Ladenburg Thalmann upgraded Repros Therapeutics (NASDAQ:RPRX) to “buy” from “neutral,” with a new price target of $5.50. The stock closed at $1.93 on Wednesday. In a new report, analyst Matthew Kaplan writes that Repros...

November 16, 2016

Feature

In conversation with Dr. Chad Larson

By Len Zehr As an advisor and consultant with Cyrex Laboratories, a clinical immunology lab, Dr. Chad Larson holds a Doctor of Naturopathic Medicine degree from Southwest College of Naturopathic Medicine and a Doctor of...

November 15, 2016

Developments

Profound Medical completes $17.4-million bought deal

Profound Medical (TSX-V:PRN) has completed a bought deal offering of 15.82 million common shares at a price of $1.10 each for gross proceeds of about $17.4-million. The offering was completed through a syndicate of...

November 14, 2016

Feature

Enumeral pursuing near-term collaborations

By Len Zehr Wael Fayad, who moved into the executive suite of Enumeral (OTCQB:ENUM) as chairman, president and CEO at the end of September, plans to reboot the company in the near term through partnering and...

November 8, 2016

Executive Moves

Jeff Sacher joins Aegis to lead firm’s healthcare banking

Jeff Sacher has joined Aegis Capital to lead the firm's global healthcare effort as a managing director.Previously, Mr. Sacher was a senior banker at Goldman Sachs, Needham and Brean Capital. In addition, he has served...

November 8, 2016

Developments

Titan Pharma’s Kate Beebe interviewed on Facebook Live

BioTuesdays’ Stephen Kilmer joins Titan management, directors and guests at the bell closing ceremony. Katherine Beebe, executive VP and chief development officer of Titan Pharmaceuticals (NASDAQ:TTNP)...

November 3, 2016

Developments

Turnstone Biologics in $41.4-million financing

Closely-held Turnstone Biologics has completed a $41.4-million series B financing led by new investor, OrbiMed, with participation from another new investor, F-Prime Capital Partners, and existing investors, FACIT and...

November 2, 2016

Executive Moves

Microbix names Jim Currie as CFO

Microbix Biosystems (TSX:MBX) appointed Jim Currie as CFO, succeeding Charles Wallace, who is retiring at the end of the year.Mr. Currie was most recently CFO of SMTC, a global electronics manufacturing services company...

November 1, 2016

Feature

NeuroproteXeon targets Q2 start of Phase 3 Xenex trial

By Len Zehr Closely-held NeuroproteXeon has received agreement on a special protocol assessment from the FDA for a Phase 3 trial of its inhaled pharmaceutical grade product, XENEX, a xenon gas formulation, as a...

November 1, 2016

Author - Leonard Zehr

Titan’s Probuphine highlighted as a potential game changer

Ladenburg upgrades Repros Therapeutics to buy

In conversation with Dr. Chad Larson

Profound Medical completes $17.4-million bought deal

Enumeral pursuing near-term collaborations

Jeff Sacher joins Aegis to lead firm’s healthcare banking

Titan Pharma’s Kate Beebe interviewed on Facebook Live

Turnstone Biologics in $41.4-million financing

Microbix names Jim Currie as CFO

NeuroproteXeon targets Q2 start of Phase 3 Xenex trial

Subscribe